Study drug before surgery for stage II-III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug called JSKN016 given before surgery to shrink non-small cell lung cancer tumors and improve outcomes. The goal is to see if this pre-treatment is safe and effective for patients with stage II-III disease that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with non-small cell lung cancer (NSCLC) that is stage II, IIIA, or IIIB and your doctor believes it can be completely removed with surgery.
- You have not had any previous cancer treatment, such as chemotherapy, radiation, or immunotherapy. (Chinese herbal medicines for cancer are allowed if stopped at least 2 weeks before.)
- Your tumor does not have certain genetic changes (EGFR mutations or ALK fusion) that are often treated with targeted drugs.
- You are in good enough health for surgery, with adequate blood counts, liver, kidney, heart, and lung function.
- You agree to use effective contraception (if applicable) for the duration of the study and for 24 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial compares two immunotherapy drugs (serplulimab and nivolumab) given before surgery for people with resectable stage II-IIIA squamous non-small cell lung cancer. The goal is to see which works better to shrink the tumor and improve outcomes.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Hear when a new NSCLC Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.